perpetual updates
https://twitter.com/disclosetv/status/1636348535460200453
Disclose.tv
@disclosetv
NEW - Fauci: Americans will likely need "a booster shot once a year."
US has the LOWEST life expectancy of all G7 nations: Alarming analysis shows America now isn't even in the world's top 50
70 years ago, the UK had one of the longest life expectancies ratings in the world
But progress stalled compared to other developed nations and it now ranks 36th
READ MORE: Countries with longest life expectancy revealed in interactive map
he US has the lowest life expectancy of all G7 nations, according to an alarming league table.
Seventy years ago people in America could expect to live until they were 68, with the country ranking 13th globally behind the likes of Norway, Sweden and Denmark.
Although the average person now lives a decade longer than in 1950, progress has stalled compared to other developed nations.
The US has since fallen to 53 on the global standings.
Britain has also fared badly, dropping from tenth to 36th in a UN list of 200 nations.
Experts suggested the sluggish progress was likely down to the health inequalities widening, resulting in poorer social groups dying earlier than the wealthy.
The graph shows how each G7 country fared in international life expectancy rankings each year from 1950 to 2020. While Japan climbed from 45th place to third, the UK slumped from 10th to 36th and the US plummeted from 13th to 53rd. It is based on data from academics from the University of Oxford and the London School of Hygiene and Tropical Medicine, who examined global life expectancy ratings
The graph shows how each G7 country fared in international life expectancy rankings each year from 1950 to 2020. While Japan climbed from 45th place to third, the UK slumped from 10th to 36th and the US plummeted from 13th to 53rd. It is based on data from academics from the University of Oxford and the London School of Hygiene and Tropical Medicine, who examined global life expectancy ratings
The average life expectancy in the UK has risen from 68.63 years in 1950 to 80.43 years in 2020, compared to 68.06 and 77.41 respectively in the US. Pictured: Aerial view of the Central Park in New York
Stagnating life expectancy of Britain and the US laid bare
66.7k viewing now
Academics from the University of Oxford and the London School of Hygiene and Tropical Medicine examined global life expectancy ratings between 1952 and 2021.
They paid particular attention to G7 nations — UK, Canada, France, Germany, Italy, Japan and the US — a collection of countries with advanced economies that represent about half of global economic output.
They found that over seven decades, the US fared the worst of all G7 countries.
While life expectancy has increased since the start of the study, similar countries have seen larger increases, according to the findings published in the Journal of the Royal Society of Medicine.
https://www.dailymail.co.uk/health/article-11866813/US-LOWEST-life-expectancy-G7-nations.html
kinda like the "war on terror", endless funding for an ambiguous enemy? they call us terrorists, will they also call us the 'antivax cartel'? the 'anti-science' cartel? why not?
https://twitter.com/CitizenFreePres/status/1636278130230046720
Citizen Free Press
@CitizenFreePres
MTG:
“I’ve co-sponsored legislation to declare war on the cartels, because they are definitely declaring war on us.”
CBDC ~ 100 days out. Announcement on the Ides of March…
Federal Reserve announces July launch for the FedNow Service
https://www.federalreserve.gov/newsevents/pressreleases/other20230315a.htm
The Service will Debut with Financial Institutions and the U.S. Treasury on Board
CHICAGO – The Federal Reserve announced that the FedNow Service will start operating in July and provided details on preparations for launch.
The first week of April, the Federal Reserve will begin the formal certification of participants for launch of the service. Early adopters will complete a customer testing and certification program, informed by feedback from the FedNow Pilot Program, to prepare for sending live transactions through the system.
Certification encompasses a comprehensive testing curriculum with defined expectations for operational readiness and network experience. In June, the Federal Reserve and certified participants will conduct production validation activities to confirm readiness for the July launch.
"We couldn't be more excited about the forthcoming FedNow launch, which will enable every participating financial institution, the smallest to the largest and from all corners of the country, to offer a modern instant payment solution," said Ken Montgomery, first vice president of the Federal Reserve Bank of Boston and FedNow program executive. "With the launch drawing near, we urge financial institutions and their industry partners to move full steam ahead with preparations to join the FedNow Service."
Many early adopters have declared their intent to begin using the service in July, including a diverse mix of financial institutions of all sizes, the largest processors, and the U.S. Treasury.
In addition to preparing early adopters for the July launch, the Federal Reserve continues to engage a range of financial institutions and service providers to complete the testing and certification program and implement the service throughout 2023 and beyond. Montgomery noted that availability of the service is just the beginning, and growing the network of participating financial institutions will be key to increasing the availability of instant payments for consumers and businesses across the country.
The FedNow Service will launch with a robust set of core clearing and settlement functionality and value-added features. More features and enhancements will be added in future releases to continue supporting safety, resiliency and innovation in the industry as the FedNow network expands in the coming years.
"With the FedNow Service, the Federal Reserve is creating a leading-edge payments system that is resilient, adaptive, and accessible," said Tom Barkin, president of the Federal Reserve Bank of Richmond and FedNow Program executive sponsor. "The launch reflects an important milestone in the journey to help financial institutions serve customer needs for instant payments to better support nearly every aspect of our economy."
About the FedNow Service
The Federal Reserve Banks are developing the FedNow Service to facilitate nationwide reach of instant payment services by financial institutions — regardless of size or geographic location — around the clock, every day of the year. Through financial institutions participating in the FedNow Service, businesses and individuals will be able to send and receive instant payments at any time of day, and recipients will have full access to funds immediately, giving them greater flexibility to manage their money and make time-sensitive payments. Access will be provided through the Federal Reserve's FedLine® network, which serves more than 10,000 financial institutions directly or through their agents. For more information, visit FedNowExplorer.org.
Last Update: March 15, 2023
https://mobile.twitter.com/dezzie_rezzie/status/1636044859243995137
https://threadreaderapp.com/thread/1636044859243995137.html
Destiny Rezendes
@dezzie_rezzie
🧵Do you really want to know who makes those Moderna Covid-19Vaccines? If you were among the millions that lined up for one. You should know some facts. Or be ignorant. Either way this is getting posted!
Destiny Rezendes
@dezzie_rezzie
·
23h
Replying to
@dezzie_rezzie
1/10 🧵Back in fall of 2021, Moderna hired and tasked a supposedly new pharmaceutical manufacturing company called National Resilience (Resilience) to make ALL of their Covid-19 vaccines . Resilience is rife with conflict of interest esp. with the intelligence community.
Destiny Rezendes
@dezzie_rezzie
·
23h
2/10 🧵 Turns out that although that is correct, National Resilience wasn't its true name and wasn't truly new either. According to http://USAspending.gov their name is Resilience Government Services Inc.
Destiny Rezendes
@dezzie_rezzie
·
23h
3/10 🧵Despite what crunchbase, or even http://USAspending.gov initially claims, Resilience wasn't founded in 2020, it was renamed. Also, it wasn't just worth 32.1 Million( usaspending) in government contracts, but closer to $2.1 Billion.
Thread
See new Tweets
Conversation
Destiny Rezendes
@dezzie_rezzie
🧵 Do you really want to know who makes those Moderna Covid-19 Vaccines? If you were among the millions that lined up for one. You should know some facts. Or be ignorant. Either way this is getting posted!
9:41 AM · Mar 15, 2023
·
243.1K
Views
1,452
Retweets
171
Quote Tweets
2,911
Likes
Destiny Rezendes
@dezzie_rezzie
·
23h
Replying to
@dezzie_rezzie
1/10 🧵Back in fall of 2021, Moderna hired and tasked a supposedly new pharmaceutical manufacturing company called National Resilience (Resilience) to make ALL of their Covid-19 vaccines . Resilience is rife with conflict of interest esp. with the intelligence community.
Destiny Rezendes
@dezzie_rezzie
·
23h
2/10 🧵 Turns out that although that is correct, National Resilience wasn't its true name and wasn't truly new either. According to http://USAspending.gov their name is Resilience Government Services Inc.
Destiny Rezendes
@dezzie_rezzie
·
23h
3/10 🧵Despite what crunchbase, or even http://USAspending.gov initially claims, Resilience wasn't founded in 2020, it was renamed. Also, it wasn't just worth 32.1 Million( usaspending) in government contracts, but closer to $2.1 Billion.
Destiny Rezendes
@dezzie_rezzie
·
23h
4/10 🧵 Now, usaspending claims that Resilience is actually named multiple entities: Nanotherapeutics, Nanosphere Inc, Ology Bioservices, and Government Resilience Services. Each entity having a vivid background.
Destiny Rezendes
@dezzie_rezzie
·
23h
5/10 🧵 They all overlap in funders, board members, and investments. 4/5 of the listed contract officers are on the board for Resilience today, which is expected. But CEO for Nanotherapeutics, Khoury, was on the BMGF board.
Destiny Rezendes
@dezzie_rezzie
·
23h
6/10 🧵 Also listed as investors is Google, Lux Capital, Magnetic Ventures. The COO for resilience was also a Senior advisor for rival Pfizer. Nanotherapeutics/Resilience's CEO of 17yrs now runs Alchem, Dr. Robert Malone's company.
Destiny Rezendes
@dezzie_rezzie
·
23h
7/10🧵Board members and Investor overlap 3x even 4x's over in their funding rounds, the SALT conference, and the SOHN conference. Also, multiple members are from BMGF, FDA, CIA, Rockefeller Univ, Merrill Lynch, Pfizer, & multi-ties to Jeffry Epstein.
Destiny Rezendes
@dezzie_rezzie
·
23h
8/10🧵 Nanosphere (Resilience) in 2015-2017 had FDA violations and given multiple warnings. Luckily for Resilience, former FDA commissioner, Scott Gottlieb sits on their board so no worries about the quality, right?!
Destiny Rezendes
@dezzie_rezzie
·
23h
9/10 🧵 Also, Nanosphere and Nanotherapeutics AKA Resilience has countless contracts with the government concerning Biological Warfare, and gene specific sensors wanted by the DoD.
Destiny Rezendes
@dezzie_rezzie
·
23h
10/10 🧵 To top it all off, Resilience was just picked in January 2023 to lead the DAVOS panel on cybersecurity. A biopharmaceutical company 🤔on cyber security? Ok sure, go get that Moderna Booster! - if you dare. mic drop
p2
https://mobile.twitter.com/dezzie_rezzie/status/1636044859243995137
https://threadreaderapp.com/thread/1636044859243995137.html
6 of 6
been done many times here.
https://www.prnewswire.com/news-releases/darpa-awards-moderna-therapeutics-a-grant-for-up-to-25-million-to-develop-messenger-rna-therapeutics-226115821.html
DARPA Awards Moderna Therapeutics A Grant For Up To $25 Million To Develop Messenger RNA Therapeutics™
CAMBRIDGE, Mass., Oct. 2, 2013 /PRNewswire/ – Moderna Therapeutics, the company pioneering messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $25 million to research and develop its messenger RNA therapeutics™ platform as a rapid and reliable way to make antibody-producing drugs to protect against a wide range of known and unknown emerging infectious diseases and engineered biological threats.
Messenger RNA therapeutics™ can be designed to tap directly into the body's natural processes to produce antibodies without exposing people to a weakened or inactivated virus or pathogen, as is the case with the vaccine approaches currently being tested. As a result, Moderna's messenger RNA therapeutics™ platform has the potential to speed the development and manufacture of treatments that can produce a safer, more reliable and more robust immune response than existing technologies.
"We are honored to be chosen by DARPA for this important grant, which will greatly accelerate our efforts to develop antibody messenger RNA therapeutics™ to combat a wide range of infectious diseases," said Stephane Bancel, president and founding CEO of Moderna. "We were awarded this major grant after an intense and rigorous scientific review, and it is a testament to our team's progress and to the profound implications of messenger RNA therapeutics™ that our work was funded. We look forward to further expanding the development of our platform into this critically important new therapeutic area."
This $24.6 million grant could support research for up to 5 years to advance promising antibody- producing drug candidates into preclinical testing and human clinical trials. The company also received a $0.7 million "seedling" grant from DARPA in March to begin work on the project.
This grant is part of a DARPA program called ADEPT: PROTECT (Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious). The goal is to develop platform technologies that can be deployed safely and rapidly to provide the U.S. population with near-immediate protection against emerging infectious diseases and engineered biological weapons, even in cases when the pathogen or infectious agent is unknown.
About DARPA
The Defense Advanced Research Projects Agency (DARPA) is the primary innovation engine of the Department of Defense. DARPA is responsible for the development of new technologies for use by the military. To deliver on its mission, DARPA challenges the status quo and thinks outside of, and well beyond, prevailing perspectives. The Agency relies on diverse performers to apply multi-disciplinary approaches to advance knowledge through basic research and to create innovative technologies that address current practical problems through applied research. DARPA is a project based agency that sets challenging objectives with their grantees to achieve revolutionary capabilities. The agency's leadership regularly weighs the progress of each program in the context of their overall portfolio to make judgment calls to either redirect funding or to accelerate specific efforts.
https://globalbiodefense.com/2014/11/18/ichor-awarded-darpa-adept-protect-contract/
Ichor Awarded DARPA ADEPT: PROTECT Contract
Ichor Medical Systems of San Diego has been awarded a contract through the Defense Advanced Research Projects Agency (DARPA) and supported by the U.S. Army Research Office for up to $20.2 million of funding over five years, including a base period award of $8.6M.
The award is part of a DARPA program called Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats (ADEPT: PROTECT) aimed at developing new platform technologies that could be safely and rapidly deployed to the U.S. population and military personnel to provide immediate protection in the event of an infectious outbreak or biological weapons attack.
The program will fund the development and clinical assessment of Ichor’s TriGrid electroporation system as a DNA-based antibody delivery platform to produce protective antibodies for passive immunoprophylaxis.
While active immunization with traditional vaccines is effective at stimulating the immune system to generate protective antibodies, such responses are not immediate and may require multiple doses of the vaccine.
In contrast, the TriGrid technology could be used to bypass the immune system to directly deliver DNA sequences encoding protective antibodies into an infected or exposed individual. This approach would result in rapid production of antibodies by the individual providing immediate protection against the pathogen.
“We are excited for this new opportunity with the Department of Defense to apply the TriGrid technology to another area of high priority for national security,” said Bob Bernard, Ichor CEO. “Whether to address unknown bioterrorist threats or pandemic disease, success of this approach would revamp traditional vaccine processes and position the TriGrid favorably for use in other broad spectrum biodefense and pandemic applications.”
Source: Ichor press release, adapted. TriGrid is a trademarked, protected term by Ichor Medical Systems
https://news.clearancejobs.com/2013/12/04/pfizer-awarded-darpa-biodefense-contract-dod-daily-contracts/
Pfizer Awarded DARPA Biodefense Contract – DoD Daily Contracts
DEFENSE ADVANCED RESEARCH PROJECTS AGENCY
Pfizer, Inc., has been awarded a $7,670,632 technology investment agreement. Pfizer shall perform a research and development program designed to develop a technology platform to identify and subsequently induce the production of protective antibodies to an emerging pathogen directly in an infected or exposed individual. Work will be performed in Cambridge, Mass. The estimated completion date is Dec. 8, 2016. Fiscal 2013 research and development funds are being obligated at time of award. The contracting activity is the Defense Advanced Research Projects Agency, Arlington, Va., (HR0011-14-3-0001).
https://www.darpa.mil/news-events/2017-02-06a
Removing the Viral Threat: Two Months to Stop Pandemic X from Taking Hold
DARPA aims to develop an integrated end-to-end platform that uses nucleic acid sequences to halt the spread of viral infections in sixty days or less
OUTREACH@DARPA.MIL
2/6/2017
Over the past several years, DARPA-funded researchers have pioneered RNA vaccine technology, a medical countermeasure against infectious diseases that uses coded genetic constructs to stimulate production of viral proteins in the body, which in turn can trigger a protective antibody response. As a follow-on effort, DARPA funded research into genetic constructs that can directly stimulate production of antibodies in the body.1,2 DARPA is now launching the Pandemic Prevention Platform (P3) program, aimed at developing that foundational work into an entire system capable of halting the spread of any viral disease outbreak before it can escalate to pandemic status. Such a capability would offer a stark contrast to the state of the art for developing and deploying traditional vaccines—a process that does not deliver treatments to patients until months, years, or even decades after a viral threat emerges.
“DARPA’s goal is to create a technology platform that can place a protective treatment into health providers’ hands within 60 days of a pathogen being identified, and have that treatment induce protection in patients within three days of administration. We need to be able to move at this speed considering how quickly outbreaks can get out of control,” said Matt Hepburn, the P3 Program Manager. “The technology needs to work on any viral disease, whether it’s one humans have faced before or not.”
Recent outbreaks of viral infectious diseases such as Zika, H1N1 influenza, and Ebola have cast into sharp relief the inability of the global health system to rapidly contain the spread of a disease using existing tools and procedures. State-of-the-art medical countermeasures typically take many months or even years to develop, produce, distribute, and administer. These solutions often arrive too late—if at all—and in quantities too small to respond to emerging threats. In contrast, the envisioned P3 platform would cut response time to weeks and stay within the window of relevance for containing an outbreak.
Key to this undertaking are nucleic-acid-based technologies—those that are centered on DNA and RNA—including some developed under DARPA’s Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program. Using these tools, scientists can identify protective antibodies from recovering patients and then, through a biological version of reverse engineering, manufacture genetic constructs that, when delivered, can instruct an individual’s body to produce similar protective antibodies. Significant quantities of these nucleic acid “blueprints” can be rapidly manufactured compared to state-of-the-art antibody production methods.
What is required now are breakthroughs in three other technology areas to bridge those past DARPA achievements and overcome the remaining bottlenecks that hinder rapid response to pandemic threats. The P3 program will pursue innovations in those three areas:
part 1
Growing virus needed to support evaluation of therapies in laboratory tests;
Subjecting antibodies to rapid rounds of evolution outside of the body to increase their potency beyond that of even the most effective antibodies obtained from infected patients; and
Developing means of efficiently delivering nucleic-acid-based protective treatments, since the technologies used to administer conventional vaccines do not readily translate.
Achieving and integrating breakthroughs in all of these areas will require choreographed cooperation among researchers and engineers specializing in such areas as immunology, microbiology, virology, medical infectious diseases, molecular biology, and medical countermeasure product development and manufacturing.
DARPA-funded teams will be required to demonstrate their integrated platforms in five simulations during the planned four-year program; they will initially test their platforms using pathogens of their choice, but ultimately they will test using DARPA-selected pathogens, including two demonstrations in which the identity of the pathogen will remain opaque to the teams until the 60-day clock starts. To ensure the developed platforms can produce a quality product with a viable pathway for regulatory review, each team will be required to complete a Phase I clinical safety trial before the end of the program.
A benefit of the nucleic-acid-based approach to limiting the spread of infection is that the genetic constructs introduced to the body would be processed quickly and would not integrate into an individual’s genome. Similarly, the antibodies produced in response to the treatment would only be present in the body for weeks to months. This is consistent with DARPA's intent with P3, which is to safely deliver transient immunity to a virus, halting the spread of disease by creating a firewall.
“Our country asks our military Service members to deploy globally and provide humanitarian assistance in all manner of high-risk environments. We owe it to them to develop the best protections possible,” said Hepburn, a U.S. Army physician who previously served as Director of Medical Preparedness on the White House National Security Staff. “If we’re successful, DARPA could take viral infectious disease outbreaks off the table as a threat to U.S. troops and as a driver of global instability.”
To further clarify the P3 program vision, answer questions from potential proposers, and facilitate teaming, DARPA is hosting two identical Proposers Days. The first will be at the Crown Plaza Tysons Corner McLean Hotel in McLean, Va., on February 22, 2017, and the second at the Doubletree by Hilton Hotel San Diego Downtown in San Diego on March 2, 2017. For registration information, visit: http://www.cvent.com/d/9vqy52.
Full details of the P3 program are included in a Broad Agency Announcement, available at: http://go.usa.gov/x9FbG. Proposal abstracts are due by 12:00 PM ET on March 13, 2017. Full proposals are due by 5:00 PM ET on May 1, 2017.
# # #
Image caption: The Pandemic Prevention Platform (P3) program aims to develop an integrated platform that uses nucleic acid sequences to halt the spread of viral infections in sixty days or less. Using nucleic-acid-based technologies pioneered by DARPA as a foundation, the program now seeks to create an end-to-end platform by developing technologies to overcome remaining bottlenecks that hinder rapid response to pandemic threats. The three required technology areas cover growth of virus to support testing of treatments; rapid evolution of protective antibodies outside of the body; and safe and efficient delivery of nucleic-acid-based protective treatments.
Media with inquiries should contact DARPA Public Affairs at outreach@darpa.mil
2 of 2
https://twitter.com/DARPA/status/819556371213484032
DARPA
@DARPA
.
@moderna_tx
has begun Phase I trials ofDARPA-funded mRNA-1325 #Zika vaccine & cleared to begin trials of mRNA-1388 #Chikungunya #vaccine
https://www.pfizer.com/b2b/suppliers/darpa
Could use some shovels on this Pfiizer/DARPA Flowdown contract, anons…
Attachment to Purchase Order Terms and Conditions (U.S. and Puerto Rico Only)
(“Attachment”)
U.S. Department of Defense – Defense Advanced Research Programs Agency (DARPA)
Required Flow-Down Terms
>Pfizer/DARPA Flowdown contract
DARPA IS ABOUT TO LAUNCH A MILITARY VERSION OF SPACEX'S STARLINK
THE FIRST SATELLITE OF THE BLACKJACK NETWORK IS LAUNCHING LATER THIS YEAR.
-
-
20
-
Blackjack Network
DARPA, the research wing of the U.S. Military, is preparing to launch an orbital mesh network similar to SpaceX's Starlink.
The first satellite for the Blackjack network will launch later this year, C4ISRNET reports. While there's still lots of testing, simulation, and launching to be done before Blackjack is complete, the move could be an important first step toward a new global military communication network.
First Of Many
Like the Starlink network, Blackjack will ultimately become a constellation of low-orbit satellites that blanket the globe.
"Blackjack seeks to develop and validate critical elements of global high-speed autonomous networks in [Low Earth Orbit]," reads a DARPA statement provided to C4ISRNET, "proving a capability that could provide the Department of Defense with highly connected, resilient, and persistent overhead coverage."
Planning Ahead
The upcoming launch of the satellite Mandrake 1, as well as the next three launches planned for 2021, will serve as prototype demonstrations for some of the technological capabilities expected of a complete Blackjack network. Those include as supercomputer processing, communication with tactical radios, and inter-satellite communication.
"It's important that we get the design right," Blackjack Program Manager Paul Thomas told C4ISRNET. "We focused first on buses and payloads, then the autonomous mission management system, which we call Pit Boss. We anticipate we'll begin integrating the first two military payloads next summer with launch via rideshare in late 2021, followed by the remainder of the Blackjack demonstration sub-constellation in 2022."
READ MORE: DARPA set to launch first Blackjack satellite later this year
DARPA set to launch first Blackjack satellite later this year
https://www.c4isrnet.com/battlefield-tech/space/2020/05/12/darpa-set-to-launch-first-blackjack-satellite-later-this-year/
The Defense Advanced Research Projects Agency will launch its first Blackjack satellite into orbit later this year, with more to follow in 2021.
With Blackjack, DARPA seeks to demonstrate the value of low earth orbit satellites for the Department of Defense. The small satellites will carry advanced technologies that will demonstrate space-based mesh networks and constellation autonomy.
“Blackjack seeks to develop and validate critical elements of global high-speed autonomous networks in LEO, proving a capability that could provide the Department of Defense with highly connected, resilient, and persistent overhead coverage,” the agency said in a May 11 statement.
The first experimental satellite will be Mandrake 1, a cubesat hosting supercomputer processing chips. Mandrake 2 will use two cubesats to demonstrate the possibility of a space-based mesh network by sharing data over optical intersatellite links. Wildcard, another payload, will experiment with links to tactical radios from orbit over a software-defined radio. A fourth unnamed experiment will host a number of advanced thirty party algorithms to test out on orbit.
“It's important that we get the design right,” said Blackjack Program Manager Paul “Rusty” Thomas. “We focused first on buses and payloads, then the autonomous mission management system, which we call Pit Boss. We anticipate we'll begin integrating the first two military payloads next summer with launch via rideshare in late 2021, followed by the remainder of the Blackjack demonstration sub-constellation in 2022.”
The agency says it is evaluating buses from Airbus, Blue Canyon Technologies and Telesat, all of which have progressed through preliminary design review. A final bus selection will be made in 2020.
SEAKR recently announced that it had been selected as the primary contractor for Pit Boss, the autonomous system behind Blackjack. Lockheed Martin will integrate the satellites.
DARPA is also looking at various payloads to be incorporated into the Blackjack constellation. Contenders include an overhead persistent infrared (OPIR) sensor from Collins Aerospace and Raytheon, radio frequency systems from Northrop Grumman, Trident and Systems and Technology Research, a position, navigation, and timing payload from Northrop Grumman, optical inter-satellite links from SA Photonics, and an electro-optical/infrared sensor from L3Harris.
Over the next few months the agency will begin running simulations with the various payloads.
“We need to show the constellations can move the right amount of data and support the data fusion and command and control we want from Pit Boss,” Thomas said. “From there, we will start building the actual hardware. By late next spring, we will have hardware and then spend next summer focused on satellite-level qualification for launch readiness in late 2021.”
The demonstration flights will be conducted in partnership with the U.S. Space Force and the Space Development Agency, an organization stood up in March 2019 to develop a new national security space architecture composed of hundreds of satellites in low earth orbit. SDA leadership has stated previously that it will build off the lessons learned from Blackjack.
https://www.fool.com/investing/general/2013/12/05/darpa-hires-pfizer-to-perform-groundbreaking-vacci.aspx
DARPA Hires Pfizer to Perform Groundbreaking Vaccine Research
For $7.7 million, DARPA wants Pfizer to rewrite the rules by which vaccines are created and diseases treated.
The Department of Defense announced eight defense contracts on Wednesday. Worth $198.4 million in total, the contracts ranged in value by a factor of 10 – from as much as $80 million to as little as $7.7 million. Yet it was that very smallest of the eight contracts awarded yesterday that was the most interesting.
The Defense Advanced Research Projects Agency (DARPA) awarded Pfizer (PFE 0.05%) a $7.7 million contract to research whether it might be possible to "identify and subsequently induce the production of protective antibodies to an emerging pathogen directly in an infected or exposed individual."
The traditional method of "curing" a disease from which DARPA is deviating involves extracting a pathogen, isolating its antigen, and using that antigen to create a vaccine in vitro. This vaccine is then injected into a patient to stimulate his or her immune system to fight off subsequent exposures to the pathogen.DARPA, however, appears to be tasking Pfizer with finding a shortcut, whereby all of this would happen in vivo, within the patient's body, thus dramatically cutting the time between the discovery of a pathogen and the military's ability to treat it. Incidentally, if Pfizer is successful in this work, its research could have significant applications in the civilian world as well.
Pfizer's DARPA contract will run through Dec. 8, 2016.
ty anon
you are a vaxxed govt employee, eh?
ecfee0 post record indicates YES.
Didn't know you benefit package included GAIDS? Now you know.
you trust trump and q? why?
your post history suggests the opposite.
so how many lies are you juggling here.
If you need someone to tell you that the govt, pharma, msm, and politricksters are liars, here is anon telling you that. Sorry anon is late.
In the past anon would have said that feeling in your chest and the back of your throat is a toxic cortisol bath, but it is probably just a mycardincidence.
>we all took shots when were kids and we're all fine.
not mrna gene editing technnologies, and MANY are NOT 'fine'. autism, auto immune diseases, cancers, neurological disorders, etc.
'trust' eugenicists, militaries, politricksters, medea, and pharmakeia?